Patents Examined by Jeanine Goldberg
  • Patent number: 11401559
    Abstract: Methods and kits are provided for screening a patient for bladder cancer. Embodiments include those involving centromeric probes to chromosomes 3, 7, and 10 and a locus-specific probe to 5p15.
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: August 2, 2022
    Assignee: LEICA BIOSYSTEMS NEWCASTLE LTD
    Inventors: Saskia Schoenmakers, Harry Schrickx, Herman Volkers
  • Patent number: 11396678
    Abstract: Disclosed herein are methods and kits for identifying a subject as having breast cancer. Also provided herein are methods and kits for determining the prognosis of a subject having breast cancer and for determining the progression of breast cancer in a subject.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: July 26, 2022
    Assignees: The Regent of the University of California, YouHealth Oncotech, Limited
    Inventors: Kang Zhang, Rui Hou, Lianghong Zheng
  • Patent number: 11384395
    Abstract: This invention intends to develop many DNA markers for a plant of the genus Fragaria and detect powdery mildew resistance with high precision by using the many DNA markers. The marker associated with powdery mildew resistance in a plant of the genus Fragaria comprises a continuous nucleic acid region sandwiched between the nucleotide sequence as shown in SEQ ID NO: 1 and the nucleotide sequence as shown in SEQ ID NO: 19 in the chromosome of the plant of the genus Fragaria.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: July 12, 2022
    Assignee: TOYOTA JIDOSHA KABUSHIKI KAISHA
    Inventors: Hiroaki Koishihara, Hiroyuki Enoki, Masayoshi Muramatsu, Satoru Nishimura, Susumu Yui, Masanori Honjo
  • Patent number: 11345949
    Abstract: Provided herein is technology relating compositions and methods for analysis of methylated DNA from a subject. The technology also relates to use of endogenous methylated DNAs as internal controls for marker gene methylation assays.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: May 31, 2022
    Assignee: Exact Sciences Corporation
    Inventors: Hatim T. Allawi, Graham P. Lidgard
  • Patent number: 11345965
    Abstract: The invention pertains to analyzing the levels of DNA methylation at specific genetic loci to detect specific body fluids, for example, vaginal secretions or vaginal epithelial cells, semen or sperms, saliva or buccal epithelial cells, or blood or blood cells. Particularly, the levels of methylation of DNA at the genetic loci corresponding to SEQ ID NOs: 1, 6, 11, and 16, more particularly, SEQ ID NOs: 25, 26, 27, and 28, are used to detect vaginal secretions or vaginal epithelial cells, semen or sperms, saliva or buccal epithelial cells, and blood or blood cells, respectively. The level of methylation at the specific loci can be determined by sequencing of the amplicons produced using specific primers designed to amplify the specific loci. Kits containing the primers and reagents for carrying out the methods disclosed herein are also provided.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: May 31, 2022
    Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Bruce McCord, Quentin Gauthier, Sohee Cho
  • Patent number: 11326214
    Abstract: The invention provides methods and compositions for the detection of Chlamydia trachomatis in a test sample. Its presence or absence in the sample is determined by nucleic acid based testing methods using primers and/or probes and or molecular beacons that bind to the 23S ribosomal genes or gene transcripts.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: May 10, 2022
    Assignee: Talis Biomedical Corporation
    Inventors: Andrea Dedent, Matt Lee, Shuyuan Ma, Hedia Maamar
  • Patent number: 11319602
    Abstract: A probe combination for detecting cancer includes one or more sets of partial hepatitis B virus (HBV) targeting probes. When sequences of each of the sets of partial HBV targeting probes are aligned, an overall sequence of the aligned set of probes matches a reference sequence of a genome of a HBV genotype or a direct repeat (DR) region on the genome. In the aligned set of probes, each of the probes overlap with one or two adjacent probes by a portion of a length of the probe. The probe combination may further includes one or more sets of hotspot gene targeting probes targeting cancer hotspot genes such as CTNNB1, TERT, and TP53 genes, one or more sets of exogenous gene targeting probes targeting portions of a lambda phage genome, and endogenous gene targeting probes targeting endogenous genes such as GAPDH and GdX genes.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: May 3, 2022
    Assignee: TCM BIOTECH INTERNATIONL CORP.
    Inventors: You-Yu Lin, Ya-Chun Wang, Sheng-Tai Tzeng
  • Patent number: 11299784
    Abstract: The present invention relates to a method for predicting the degree of weight loss attainable by applying one or more dietary interventions to a subject and/or the degree of maintenance of weight loss following one or more dietary interventions; which method comprises determining the level of microRNA-486 (miR-486) in one or more samples obtained from the subject; and/or determining the nucleotide of the subject at one or more polymorphic positions genetically linked to miR-486.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: April 12, 2022
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Armand Valesia, Jorg Hager, Jerome Carayol
  • Patent number: 11286527
    Abstract: The present invention relates to methods for detecting a genetic deletion at the SHOX locus of a horse, where the presence of such a genetic deletion indicates that the horse is a carrier of disease-causing mutation that can lead to skeletal atavism. The invention further provides nucleic acid primers and probes for use in methods for detecting the presence or absence of disease-causing genetic deletion at the SHOX locus of a horse.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: March 29, 2022
    Assignees: CAPILET GENETICS AB, UNIVERSITY OF WASHINGTON
    Inventors: Sofia Mikko, Leif Andersson, Gabriella Lindgren, Carl-Johan Rubin, Bhanu Chowdhary, Terje Raudsepp, Evan E. Eichler, John Huddleston, Maika Malig
  • Patent number: 11268133
    Abstract: Disclosed herein are methods of detecting presence of a gene fusion in a sample from a subject. In some embodiments, the methods of detecting presence of a fusion gene in a sample from a subject utilize a fusion probe that spans the point of fusion between two nucleic acids or genes. In other embodiments, the methods of detecting presence of a fusion gene in a sample from a subject utilize two or more probes that flank the point of fusion between two nucleic acids or genes. In additional embodiments, the methods can include determining the percentage of gene fusion in the sample relative to the first nucleic acid or the second nucleic acid.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: March 8, 2022
    Assignee: HTG Molecular Diagnostics, Inc.
    Inventors: Bruce A. Seligmann, BJ Kerns, John Luecke, Matt Rounseville, Ihab Botros, Mark Schwartz
  • Patent number: 11268148
    Abstract: Disclosed herein are methods for determining inflammation in subjects. Also disclosed are methods for determining whether a subject has sepsis. The methods include determining methylation of preproinsulin DNA and chromatin target of PRMT1 (CHTOP).
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: March 8, 2022
    Assignee: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventor: Raghavendra G. Mirmira
  • Patent number: 11261497
    Abstract: The invention provides PRKC gene fusions, PRKC fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with PRKC fusions, such as conditions mediated by aberrant PRKC expression or activity, or overexpression of PRKC.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: March 1, 2022
    Assignee: Blueprint Medicines Corporation
    Inventors: Nicolas Stransky, Joseph L. Kim
  • Patent number: 11261482
    Abstract: The present invention relates to a composition for detecting an epidermal cell growth factor receptor gene mutation and to a kit comprising the composition and, more specifically, to a primer and probe set composition for detecting an epidermal cell growth factor gene mutation, and to a kit for detecting an EGFR gene mutation, comprising the composition. A method according to the present invention can not only predict and diagnose responsiveness to a therapeutic agent for the prognosis of a cancer patient, but also predict a cancer metastasis or relapse Thus, the method can be useful for the purposes of determining the need to administer an anticancer therapeutic agent and guiding the direction of future treatment, and for monitoring a cancer metastasis or relapse.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: March 1, 2022
    Assignee: GENCURIX INC
    Inventors: Young Kee Shin, Bohyun Byun, Hyunjeung Choi, Joon Seok Choi, Young Ho Moon, Jong Heun Lee, Sang Rea Cho, Jee Eun Kim, Myungsun Kim
  • Patent number: 11248261
    Abstract: The present invention relates to the identification of a novel allele of the RHD gene associated with a weak D phenotype and the kits and methods for detecting this allele.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: February 15, 2022
    Assignees: ETABLISSEMENT FRANCAIS DU SANG, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), NATIONAL INSTITUTE OF IMMUNOHAEMATOLOGY, UNIVERSITE DE BRETAGNE OCCIDENTALE (UBO)
    Inventors: Yann Fichou, Swati Kulkarni
  • Patent number: 11230729
    Abstract: Efficient harvesting of cells, cell fragments, free nuclei, and DNA material from female reproductive system is made possible by processing gelatinous part of cervical mucus. Rinsing may be used to separate the gelatinous part of cervical mucus from the remainder of the cervical mucus sample.
    Type: Grant
    Filed: February 17, 2019
    Date of Patent: January 25, 2022
    Assignee: INANNA DIAGNOSTICS, INC
    Inventor: Maya Tevlin
  • Patent number: 11225692
    Abstract: Described herein various PCR based assays that can detect H. penaei and/or V. parahaemolyticus that causes AHPND in a nucleic acid sample obtained from one or more shrimp. In some aspects, the PCR based assays can detect one or more of the following genes: the flgE gene from H. penaei, the shrimp 18s rRNA gene, the shrimp beta actin gene from shrimp, a bacterial 16S rRNA gene from bacteria (any type of bacteria) the Vibrio pirA gene, and the Vibrio pirB gene. The assays described herein can be single assays or can be multiplexed such that more than one gene and/or more than one bacterial species can be detected in a single reaction. Other compositions, compounds, methods, features, and advantages of the present disclosure will be or become apparent to one having ordinary skill in the art upon examination of the following drawings, detailed description, and examples.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: January 18, 2022
    Assignee: Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: Luis F. Aranguren Caro, Arun Dhar, Roberto Cruz Flores
  • Patent number: 11220709
    Abstract: Described herein are methods for determining a sequence of a region of interest from an mRNA molecule. Sequenced polynucleotides can include a barcode region, a homopolymer region (e.g., a poly-A region), and a target region associated with the mRNA molecule. According to some methods, the barcode region omits the same base present in the homopolymer region. According to some methods, extension of the primer used for sequencing is stalled within the homopolymer region. According to some methods, sequencing flow cycles and the different barcode regions of the polynucleotides configured are such that the primer is extended to the end of the barcode region across the plurality of polynucleotides before being extended into the homopolymer region. According to some methods, two primers or a cleavable primer is used to separately sequence the barcode region and the target region.
    Type: Grant
    Filed: January 26, 2021
    Date of Patent: January 11, 2022
    Assignee: ULTIMA GENOMICS, INC.
    Inventors: Florian Oberstrass, Gilad Almogy
  • Patent number: 11203784
    Abstract: A method of detecting death of a cell type or tissue in a subject is disclosed. The method comprises determining whether cell-free DNA comprised in a fluid sample of the subject is derived from the cell type or tissue, wherein the determining is effected by ascertaining the methylation status of at least four methylation sites on a continuous sequence of the cell-free DNA, the sequence comprising no more than 300 nucleotides, wherein a methylation status of each of the at least four methylation sites on the continuous sequence of the DNA characteristic of the cell type or tissue is indicative of death of the cell type or tissue. Kits for detecting cell death are also disclosed.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: December 21, 2021
    Assignees: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Yuval Dor, Ruth Shemer, Benjamin Glaser
  • Patent number: 11203789
    Abstract: A method for detecting a bacterium of the genus Novosphingobium, includes a first step of amplifying nucleotides using a test DNA as a template and primers capable of amplifying a nucleotide sequence of consecutive 94 or more nucleotides and 136 or less nucleotides in the nucleotide sequence of SEQ ID NO: 1 to obtain an amplified product; and a second step of detecting the amplified product.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: December 21, 2021
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventor: Tomokazu Mitsui
  • Patent number: 11186878
    Abstract: A method for analyzing cell free DNA (cfDNA) from the bloodstream of a cancer patient is provided. In some embodiments, the method may comprise sequencing at least part of the coding sequences of TP53 and KRAS in a sample of the cfDNA, analyzing the sequences to identify nucleotide transversions in the coding sequences of the genes, relative to reference sequences of the genes. In some embodiments, the method may comprise counting the total number of identified nucleotide transversions. The presence of nucleotide transversions indicates that the patient will be more responsive to the immune checkpoint inhibitor, whereas a decreased number of transversions or no transversios indicates that the patient will be less responsive to the immune checkpoint inhibitor.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: November 30, 2021
    Assignee: INIVATA LTD.
    Inventors: John Beeler, Vincent Plagnol, Greg Jones